Endocrine Abstracts

Background: Prader-Willi syndrome (PWS) is the most frequent genetic cause of obesity and is often complicated by glucose metabolism alterations. Conventional therapies prescribed in type 2 diabetes mellitus (T2DM), like oral hypoglycemic agents and insulin, frequently failed to achieve adequate glycemic control in patients with PWS. Beneficial effects of the glucagon like peptide-1 receptor agonists (GLP1RAs) exenatide and liraglutide have been reported for the management of ...